Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial
Abstract
PURPOSE Stereotactic radiation (SRS/SRT) as opposed to whole-brain radiation (WBRT) represents the standard of care for patients with a limited number of brain metastases given the relatively favorable toxicity profile associated with stereotactic treatment. However, in patients with small cell lung cancer (SCLC), WBRT remains standard because of a lack of prospective data supporting SRS/SRT and concerns related to intracranial progression and neurologic death when WBRT is omitted. We conducted a single-arm, multicenter, phase II trial of SRS/SRT in patients with SCLC and 1-10 brain metastases to assess neurologic death rates relative to historical controls managed with WBRT (ClinicalTrials.gov identifier: NCT03391362 ). METHODS Patients were eligible if they had SCLC or an extrathoracic small cell primary and 1-10 brain metastases. Previous brain-directed radiation including prophylactic cranial irradiation was not permitted. Neurologic death was defined as marked, progressive, radiographic brain progression accompanied by corresponding neurologic symptomatology without systemic disease progression or systemic symptoms of a life-threatening nature. Close imaging-based surveillance of the brain post-SRS/SRT was used. RESULTS Between February 2018 and April 2023, 100 patients were enrolled. The median number of brain metastases was 2 (IQR, 1-4; range, 1-10). The median overall survival was 10.2 months; only 22% of patients required salvage WBRT. In total, 20 neurologic deaths were observed, relative to 64 non-neurologic deaths. The neurologic death rate at 1 year was 11.0% (95% CI, 5.8 to 18.1); the historical rate in patients managed with WBRT was 17.5%. CONCLUSION Our prospective, multi-institutional study demonstrated low rates of neurologic death when SRS/SRT as opposed to WBRT is used in patients with SCLC and 1-10 brain metastases who are surveilled closely post-treatment, supporting the utility of stereotactic approaches in this population.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (23)
Ayal A. Aizer
Ayal A. Aizer, MD, MHS, Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA; Paul J. Catalano, ScD, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA; and Rifaquat Rahman, MD, Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA
Shyam K. Tanguturi
Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA
Diana D. Shi
Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Paul J. Catalano
Kee-Young Shin
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
Ivy Ricca
Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA
Marciana Johnson
Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA
Grant Benham
Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA
David E. Kozono
Raymond H. Mak
Lauren Hertan
Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA
Fallon Chipidza
Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA
Monica Krishnan
Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA
Itai Pashtan
Luke Peng
26Northeastern University, Boston, United States
Jack M. Qian
Ron Y. Shiloh
Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA
Daniel N. Cagney
Department of Radiation Oncology, Mater Private Hospital, Dublin, Ireland
Jacob Sands
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Paul D. Brown
Patrick Y. Wen
Daphne A. Haas-Kogan
Rifaquat Rahman
Brigham and Women's Hospital, Boston, MA